266 related articles for article (PubMed ID: 31483485)
1. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Higano CS; Armstrong AJ; Sartor AO; Vogelzang NJ; Kantoff PW; McLeod DG; Pieczonka CM; Penson DF; Shore ND; Vacirca J; Concepcion RS; Tutrone RF; Nordquist LT; Quinn DI; Kassabian V; Scholz MC; Harmon M; Tyler RC; Chang NN; Tang H; Cooperberg MR
Cancer; 2019 Dec; 125(23):4172-4180. PubMed ID: 31483485
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.
Wei XX; Kwak L; Hamid A; He M; Sweeney C; Flanders SC; Harmon M; Choudhury AD
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):314-319. PubMed ID: 35145218
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
4. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
Sartor O; Armstrong AJ; Ahaghotu C; McLeod DG; Cooperberg MR; Penson DF; Kantoff PW; Vogelzang NJ; Hussain A; Pieczonka CM; Shore ND; Quinn DI; Small EJ; Heath EI; Tutrone RF; Schellhammer PF; Harmon M; Chang NN; Sheikh NA; Brown B; Freedland SJ; Higano CS
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):517-526. PubMed ID: 32111923
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.
McKay RR; Hafron JM; Ferro C; Wilfehrt HM; Fitch K; Flanders SC; Fabrizio MD; Schweizer MT
Adv Ther; 2020 Dec; 37(12):4910-4929. PubMed ID: 33029725
[TBL] [Abstract][Full Text] [Related]
6. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
[TBL] [Abstract][Full Text] [Related]
7. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
Small EJ; Higano CS; Kantoff PW; Whitmore JB; Frohlich MW; Petrylak DP
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):259-64. PubMed ID: 24957547
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer.
Caram MEV; Ross R; Lin P; Mukherjee B
JAMA Netw Open; 2019 Apr; 2(4):e192589. PubMed ID: 31002323
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
Gong CL; Hay JW
J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.
Chowdhury S; Bjartell A; Lumen N; Maroto P; Paiss T; Gomez-Veiga F; Birtle A; Kramer G; Kalinka E; Spaëth D; Feyerabend S; Matveev V; Lefresne F; Lukac M; Wapenaar R; Costa L
Target Oncol; 2020 Jun; 15(3):301-315. PubMed ID: 32500294
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
Marshall CH; Fu W; Wang H; Park JC; DeWeese TL; Tran PT; Song DY; King S; Afful M; Hurrelbrink J; Manogue C; Cotogno P; Moldawer NP; Barata PC; Drake CG; Posadas EM; Armstrong AJ; Sartor O; Antonarakis ES
Clin Cancer Res; 2021 Mar; 27(6):1623-1630. PubMed ID: 33451978
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
George DJ; Sartor O; Miller K; Saad F; Tombal B; Kalinovský J; Jiao X; Tangirala K; Sternberg CN; Higano CS
Clin Genitourin Cancer; 2020 Aug; 18(4):284-294. PubMed ID: 32057714
[TBL] [Abstract][Full Text] [Related]
15. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
Simpson EL; Davis S; Thokala P; Breeze PR; Bryden P; Wong R
Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Small EJ; Lance RS; Gardner TA; Karsh LI; Fong L; McCoy C; DeVries T; Sheikh NA; GuhaThakurta D; Chang N; Redfern CH; Shore ND
Clin Cancer Res; 2015 Sep; 21(17):3862-9. PubMed ID: 25925891
[TBL] [Abstract][Full Text] [Related]
17. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
18. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
[TBL] [Abstract][Full Text] [Related]
19. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
20. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
McNeel DG; Gardner TA; Higano CS; Kantoff PW; Small EJ; Wener MH; Sims RB; DeVries T; Sheikh NA; Dreicer R
Cancer Immunol Res; 2014 Oct; 2(10):988-99. PubMed ID: 25189164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
